Health and Healthcare

Teva : TEVA

All Teva Articles

450 Articles

Chris Lange | Feb 5, 2015 at 10:10 AM EST

Are Teva’s Earnings Good Enough?

Prior to the markets opening Thursday, Teva Pharmaceutical reported its most recent financial results.

Chris Lange | Feb 1, 2015 at 8:56 AM EST

The Top 10 Corporate Earnings for the Week Ahead

24/7 Wall St. has put together a preview of some of the larger companies reporting quarterly results in the coming…

Jon C. Ogg | Jan 26, 2015 at 4:53 PM EST

Is a Generic Nexium Purple Pill for You?

Teva Pharmaceutical announced on Monday that the FDA approved the first generic equivalent to Nexium delayed-release capsules in the United…

Jon C. Ogg | Dec 17, 2014 at 1:05 PM EST

Is a Biosimilar (Generic) Top Cancer Drug for You?

A biosimilar application filing from Apotex has been accepted by the Food and Drug Administration for version of Amgen's Neulasta.

Jon C. Ogg | Dec 12, 2014 at 8:25 AM EST

Top Analyst Upgrades and Downgrades: Citrix, GoPro, HP, Microsoft, Oracle, Teva and More

Friday's top analyst upgrades, downgrades and initiations include Citrix Systems, GoPro, Hewlett-Packard, Microsoft, Oracle and Teva Pharmaceutical.

Lee Jackson | Oct 21, 2014 at 8:45 AM EDT

Cowen’s Sell-Off Shopping List Loaded With Stocks With Huge Upside Potential

Cowen asked the analysts which stocks should be on their shopping lists. Here are the six with the biggest upside…

Jon C. Ogg | Jul 23, 2014 at 8:45 AM EDT

Top Analyst Upgrades and Downgrades: DuPont, GE, King, Microsoft, Xilinx, McDonald’s and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include…

Lee Jackson | Jul 18, 2014 at 10:15 AM EDT

UBS Lists 6 Stocks With Positive Catalysts Coming Soon

In a recent research report, UBS specifically mentions six companies that it advises investors not to use an option strategy…

Jon C. Ogg | Jun 27, 2014 at 8:20 AM EDT

Top Analyst Upgrades and Downgrades: Alcoa, Cigna, Intel, Molina, Teva, UnitedHealth and More

These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Friday, June 27, 2014. They include…

Jon C. Ogg | May 1, 2014 at 8:45 AM EDT

Why Teva Sees a Sell-the-News Reaction to Decent Earnings

Teva Pharmaceutical is finding a bit of a sell-the-news reaction to its first-quarter earnings report. The company said revenues rose…

Trey Thoelcke | Apr 22, 2014 at 9:50 AM EDT

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

The specialty pharmaceutical sector is exploding with news of takeovers, exchanges and possible mergers. Here are some of the top…

Jon C. Ogg | Apr 22, 2014 at 8:35 AM EDT

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

These are the top analyst upgrades, downgrades and initiations for Tuesday, April 22, 2014. They include AMD, ARM Holdings, Barrick…

Trey Thoelcke | Mar 31, 2014 at 12:50 PM EDT

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to…

Jon C. Ogg | Mar 19, 2014 at 8:15 AM EDT

Top Analyst Upgrades and Downgrades: Compugen, Juniper Networks, Suncor, Yingli and More

These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on March 19, 2014. They…

cgblaine22 | Mar 14, 2014 at 11:05 AM EDT

Why Teva May Be Back From the Dead

Two analyst upgrades on Friday, a new CEO and a 33% increase in its stock price since November may be…

1 … 20 21 22 23 24 … 30

Teva : TEVA

All Teva Articles

Are Teva’s Earnings Good Enough?

The Top 10 Corporate Earnings for the Week Ahead

Is a Generic Nexium Purple Pill for You?

Is a Biosimilar (Generic) Top Cancer Drug for You?

Top Analyst Upgrades and Downgrades: Citrix, GoPro, HP, Microsoft, Oracle, Teva and More

Cowen’s Sell-Off Shopping List Loaded With Stocks With Huge Upside Potential

Top Analyst Upgrades and Downgrades: DuPont, GE, King, Microsoft, Xilinx, McDonald’s and More

UBS Lists 6 Stocks With Positive Catalysts Coming Soon

Top Analyst Upgrades and Downgrades: Alcoa, Cigna, Intel, Molina, Teva, UnitedHealth and More

Why Teva Sees a Sell-the-News Reaction to Decent Earnings

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

Teva’s Latest Victory in Effort to Protect Key Patents

Top Analyst Upgrades and Downgrades: Compugen, Juniper Networks, Suncor, Yingli and More

Why Teva May Be Back From the Dead

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Teva : TEVA

All Teva Articles

Are Teva’s Earnings Good Enough?

The Top 10 Corporate Earnings for the Week Ahead

Is a Generic Nexium Purple Pill for You?

Is a Biosimilar (Generic) Top Cancer Drug for You?

Top Analyst Upgrades and Downgrades: Citrix, GoPro, HP, Microsoft, Oracle, Teva and More

Cowen’s Sell-Off Shopping List Loaded With Stocks With Huge Upside Potential

Top Analyst Upgrades and Downgrades: DuPont, GE, King, Microsoft, Xilinx, McDonald’s and More

UBS Lists 6 Stocks With Positive Catalysts Coming Soon

Top Analyst Upgrades and Downgrades: Alcoa, Cigna, Intel, Molina, Teva, UnitedHealth and More

Why Teva Sees a Sell-the-News Reaction to Decent Earnings

Jefferies Initiates Coverage on Specialty Pharmaceutical Takeover Candidates

Top Analyst Upgrades and Downgrades: AMD, ARM, Barrick, Netflix, Teva, Valero and More

Teva’s Latest Victory in Effort to Protect Key Patents

Top Analyst Upgrades and Downgrades: Compugen, Juniper Networks, Suncor, Yingli and More

Why Teva May Be Back From the Dead

Mark Cuban’s Dire Prediction: Could These Trade Policies Trigger a Recession Worse Than 2008?

XRP Price: XRP ETFs Snapped Their Longest Inflow Streak of 2026 as Price Slips Below $1.40

Jim Cramer to Brinker’s CEO: How Do You Make More Money When Every Cost Is Going the Wrong Way?

Featured Reads

Retirees Are Realizing a $1.5 Million Nest Egg at 60 Only Means $31,000 in Real Annual Spending

71% of Americans With Financial Advisors Feel Secure. Only 10% Without One Do